Eton Pharmaceuticals’ (ETON) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Eton Pharmaceuticals (NASDAQ:ETON) in a research report report published on Wednesday morning,Benzinga reports. They currently have a $11.00 target price on the stock. HC Wainwright also issued estimates for Eton Pharmaceuticals’ Q1 2025 earnings at $0.09 EPS, Q2 2025 earnings at $0.09 EPS, Q3 2025 earnings at $0.12 EPS, Q4 2025 earnings at $0.14 EPS, FY2026 earnings at $0.85 EPS, FY2027 earnings at $1.13 EPS and FY2028 earnings at $1.28 EPS.

Separately, Craig Hallum raised their target price on shares of Eton Pharmaceuticals from $10.00 to $15.00 and gave the company a “buy” rating in a research report on Monday, October 28th.

Eton Pharmaceuticals Trading Down 4.2 %

ETON opened at $10.02 on Wednesday. The company has a market cap of $258.92 million, a P/E ratio of -45.55 and a beta of 1.25. The company’s 50 day moving average is $7.40 and its 200-day moving average is $4.98. Eton Pharmaceuticals has a 1-year low of $3.03 and a 1-year high of $11.11.

Insider Buying and Selling at Eton Pharmaceuticals

In other Eton Pharmaceuticals news, major shareholder Opaleye Management Inc. bought 11,248 shares of Eton Pharmaceuticals stock in a transaction on Monday, October 7th. The shares were purchased at an average cost of $7.22 per share, with a total value of $81,210.56. Following the acquisition, the insider now directly owns 2,730,000 shares of the company’s stock, valued at $19,710,600. The trade was a 0.41 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders bought 85,600 shares of company stock worth $462,674. 14.89% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Eton Pharmaceuticals

Several large investors have recently modified their holdings of ETON. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Eton Pharmaceuticals in the third quarter worth $54,000. Jane Street Group LLC acquired a new position in Eton Pharmaceuticals during the 3rd quarter worth about $90,000. Renaissance Technologies LLC grew its position in shares of Eton Pharmaceuticals by 63.8% in the 2nd quarter. Renaissance Technologies LLC now owns 106,500 shares of the company’s stock valued at $350,000 after buying an additional 41,469 shares during the last quarter. Stonepine Capital Management LLC bought a new stake in shares of Eton Pharmaceuticals in the 2nd quarter valued at about $362,000. Finally, Connor Clark & Lunn Investment Management Ltd. increased its stake in shares of Eton Pharmaceuticals by 86.6% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 65,014 shares of the company’s stock valued at $390,000 after buying an additional 30,167 shares during the period. Institutional investors own 27.86% of the company’s stock.

Eton Pharmaceuticals Company Profile

Eton Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1.